Category: Guest content

Treat pharma as a utility, and 10 other ways states can lower drug prices

As prescription drug costs continue to squeeze state budgets, a group of state health policy makers is offering some novel – and also some familiar – suggestions for coping. These include regulating the pharmaceutical industry as a utility, allowing states to operate as pharmacy benefit managers and waiving some provisions of the Medicaid program. In […]





Process Validation and Its Need in the Biotechnology Industry

This is a guest post from Edward Simpson, a seasoned calibration and technical engineer. Do you have a response to Edward’s post? Respond in the comments section below. Process validation is a crucial component of cGMP (current Good Manufacturing Practice) in industries concerned with public health and safety, such as pharma, bio-pharma and biotech.  What […]




Click here for reuse options!
Copyright 2016 Biotechblog

Making sense of drug names

This is a guest post from DrugPatentWatch. Do you have a response to DrugPatentWatch’s post? Respond in the comments section below. A drug by any other name would work just as well… In William Shakespeare’s play Romeo and Juliet, Juliet uses the phrase “A rose by any other name would smell just as sweet” to argue […]




Click here for reuse options!
Copyright 2016 Biotechblog

Formulary Best Practice: Cost Containment through Generic Drugs

This is a guest post from DrugPatentWatch. Do you have a response to DrugPatentWatch’s post? Respond in the comments section below. Effects of generic competition in pharmaceuticals are more complex than they used to be Cost containment has been a major aspect of the Affordable Care Act (ACA), with incentives for reducing hospital readmissions and pressure […]




Click here for reuse options!
Copyright 2016 Biotechblog

Branding Biotech – Communicating the Brand’s Point of Differentiation

This is a guest post from Brannon Cashion, President of Addison Whitney Health. Do you have a response to Brannin’s post? Respond in the comments section below. The branding process in the biotech sector can be related to the oxymoronic term of “new and improved.” While there is great benefit to being new, and also to […]




Click here for reuse options!
Copyright 2016 Biotechblog

Biosimilar Naming: Distinguishable or Disingenuous?

This is a guest post from Robert Yapundich, MD and Gregory Schimizzi, MD. Dr. Yapundich is a practicing neurologist in Hickory, North Carolina and a member of the Alliance for Patient Access. Dr Schimizzi is a practicing rheumatologist, treasurer of the Coalition of State Rheumatology Organizations and co-convener of the Biologics Prescribers Collaborative. Distinguishable biosimilar naming was the top issue for […]




Click here for reuse options!
Copyright 2016 Biotechblog

Mainstreaming the Microbiome

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. Towards the end of 2015, I wrote about growing recognition of the importance of the microbiome for human health and consequently for commercial biopharmaceutical development here.  Still microbiome research […]




Click here for reuse options!
Copyright 2016 Biotechblog

Lean, Mean, Startup, Machine

This paper is a final project from the NIH Foundation for Advanced Education in the Sciences course — TECH 566: Biotechnology Management Starting up a company is a risky endeavor. From listening to the FAES 566’s course panel discussions this semester, it is clear that there are many challenges a Chief Executive Officer (CEO) will face […]




Click here for reuse options!
Copyright 2015 Biotechblog

Biotechnology in Countries Beginning with “I” – Part 9: Iran

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. Looking beyond the landmark nuclear deal, Iranian media sources are trumpeting the Islamic State’s prowess in biotechnology.  So how does Iran really measure up – globally and compared to […]




Click here for reuse options!
Copyright 2015 Biotechblog

The Paradox of Pharmaceutical Hyperconnectivity

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. As we head into the dog days of summer I continue to reflect on the  recent DIA and BIO annual meetings held in mid-June. At both events I was […]




Click here for reuse options!
Copyright 2015 Biotechblog

%d bloggers like this: